Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Leases: 2019-2022

Historic Operating Leases for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to $6.6 million.

  • ADC Therapeutics' Operating Leases rose 52.16% to $10.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.1 million, marking a year-over-year increase of 52.16%. This contributed to the annual value of $6.6 million for FY2022, which is 18.19% down from last year.
  • As of FY2022, ADC Therapeutics' Operating Leases stood at $6.6 million, which was down 18.19% from $8.0 million recorded in FY2021.
  • Over the past 5 years, ADC Therapeutics' Operating Leases peaked at $8.0 million during FY2021, and registered a low of $5.0 million during FY2019.
  • In the last 2 years, ADC Therapeutics' Operating Leases had a median value of $7.3 million in 2021 and averaged $7.3 million.
  • Data for ADC Therapeutics' Operating Leases shows a maximum YoY decreased of 18.19% (in 2022) over the last 5 years.
  • Over the past 3 years, ADC Therapeutics' Operating Leases (Yearly) stood at $5.0 million in 2019, then reached $8.0 million in 2021, then fell by 18.19% to $6.6 million in 2022.